Key result
The GPIa T allele was more frequent in ACS patients than controls and was associated with significantly higher platelet aggregation and reduced sensitivity to dual antiplatelet treatment.
Why the study?
Does the GPIa C807T polymorphism affect platelet function and sensitivity to dual antiplatelet treatment in patients with acute coronary syndrome?
Population
220 patients diagnosed with acute coronary syndrome (ACS) and 220 healthy controls (total n=440).
Comparison
Dual antiplatelet treatment. vs Different GPIa C807T genotypes and healthy…
Design
Case-control
Authors
Loading...
GPIa T allele may mark heightened DAPT resistance in ACS; leaves open whether genotyping should guide therapy.
Case-Control (n=440)
Does the GPIa C807T polymorphism affect platelet function and sensitivity to dual antiplatelet treatment in patients with acute coronary syndrome?
The GPIa C807T polymorphism, specifically the T allele, is associated with increased platelet aggregation and reduced sensitivity to dual antiplatelet therapy in ACS patients, suggesting a need for more aggressive antithrombotic treatment in this subgroup.
Zhang et al. (2015) conducted a case-control in Acute Coronary Syndrome (ACS) (n=440). Glycoprotein Ia (GPIa) C807T polymorphism vs. Healthy controls / C allele was evaluated on Platelet aggregation and plasma concentrations of α-granule membrane protein (GMP-140). The GPIa T allele was more frequent in ACS patients than controls and was associated with significantly higher platelet aggregation and reduced sensitivity to dual antiplatelet treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: